Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients

Journal of Thrombosis and Thrombolysis

Volumn 23, Issue 1, 2007, Pages 31-34

  Eroglu, Aydan ^a   Ulu, Arzu ^b   Çam, Ragip ^b   Kurtman, Cengiz ^b   Akar, Nejat ^b  

^a Numune State Hospital   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Cancer; FVL; PT G20210A; Thromboembolism

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; GLYCINE; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA DETERMINATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33846989362     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-9001-z     Document Type: Article

References (19)

1. Dahlback B (1995) New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gln mutation in Factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 74:139-148
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased in venous thrombosis. Blood 88:3698-3703
3. Seligsohn U, Lubetsky A (2001) Genetic suspectibility to venous thrombosis. New Engl J Med 344:1222-1231
4. Levine MN, Lee AY, Kakkar AK (2003) From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 1:1456-1463
5. Lee AY, Levine MN (1999) The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 25:137-145
6. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ (1996) Clinical significance of the FV: Q 506 mutation in unselected oncology patients. Am J Med 101:406-412
7. Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacobson LJ, Manco-Johnson MJ (1997) The factor V Leiden mutation in children with cancer and thrombosis. Brit J Haematol 96:484-489
8. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B (2001) Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110:91-96
9. Ravin AJ, Edwards RP, Krohn MA, Kelley JR, Christopherson WA, Roberts JM (2002) The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 100:1285-1289
10. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P, Hiller E (2002) Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 94:3120-3126
11. Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson PR, del Giglio A, Franco RF (2003) Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 109:171-174
12. Mandala M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A (2004) Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 15:590-593
13. Eroglu A, Kurtman C, Ulu A, Cam R, Akar N (2005) Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis. J Thromb Haemost 3:1323-1324
14. Kennedy M, Andreescu ACM, Greenblatt MS, Jiang H, Thomas CA, Chassereau L, Wong C, Durda P, Cushman M (2005) Factor V Leiden, prothrombin 20210 and the risk of venous thrombosis among cancer patients. Brit J Haematol 128:386-388
15. Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722
16. Eroglu A, Cam R, Yildiz Z, Akar N (2003) PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer. Thromb Res 111:317-319
17. Donati MB, Falanga A. (2001) Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 106:18-24
18. Gale AJ, Gordon SG (2001) Update on tumor cell procoagulant factors. Acta Haematol 106:25-32
19. Akar N, Akar E, Dalgin G, Sözüöz K, Ömrü K, Cin Ş (1997) Frequency of factor V (1691 G-A) mutation in Turkish population. Thromb Haemost 78:1527-1528